PSTI - Pluristem Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.27
+0.01 (+0.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.26
Open1.25
Bid1.20 x 3200
Ask1.27 x 800
Day's Range1.24 - 1.27
52 Week Range1.10 - 2.12
Volume134,092
Avg. Volume470,739
Market Cap140.804M
Beta1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateFeb 15, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Pluristem Initiates Two Pivotal Phase III Studies in Israel

    HAIFA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that Israel’s Ministry of Health has cleared the Company to commence patient recruitment in Israel for two ongoing pivotal Phase III trials of PLX-PAD cell therapy, one for the treatment of Critical Limb Ischemia (CLI) and another for the treatment of muscle injury following hip fracture surgery. Both trials have been accepted to accelerated approval pathways and have received a total of $16.7 million in grants from the European Union’s Horizon 2020 Program. “We are pleased to open clinical sites in Israel for both of our ongoing pivotal Phase III studies.

  • Benzinga20 days ago

    Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

    With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst  George ...

  • GlobeNewswire26 days ago

    Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that the Japan Patent Office has granted Pluristem a patent for the treatment of Acute Radiation Syndrome (ARS) and its impact on the gastrointestinal tract. The patent titled “Methods for Treating Radiation or Chemical Injury” relates to intramuscular (IM) administration of adherent stromal cells, cultured under three-dimensional culturing conditions, for mitigating intestinal damage in patients that have been exposed to radiation or chemotherapy.

  • ACCESSWIRElast month

    Free Technical Reports on Portola Pharma and Three Additional Biotech Equities

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).

  • GlobeNewswirelast month

    Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. Together, the companies hope to transform cell therapy manufacturing into a large-scale, high capacity industry that will enable the production of millions of therapeutic doses of regenerative medicines.

  • MarketWatch2 months ago

    Pluristem shares jump 2% on news of positive trial of treatment for radiation damage

    The Israeli company, which develops placenta-based cell therapies, said a study conducted with Fukushima Medical University of its PLX-R18 cells as a treatment for radiation damage to the gastrointestinal tract and bone marrow found that they significantly increase survival rates, preserve GI stem cells activity that improve the recovery of the system and prevent severe damage to the intestinal lining. The company said the cells may have potential as a multi-organ treatment for acute radiation syndrome, or ARS. "Lethality in ARS originates mainly from radiation-induced injuries to bone marrow and the GI tract, highlighting the importance of the study's purpose and results," Akihiro Inano, Ph.D. of Fukushima University, said in a statement.

  • GlobeNewswire2 months ago

    Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. Data from these studies showed that PLX-R18 cells significantly increase survival rates, preserve GI stem cells activity that enhance the recovery of the GI system and prevents severe damage to the intestinal lining, suggesting PLX-R18 potential as a multi-organ therapy for acute radiation syndrome (ARS). Under a Memorandum of Understanding (MOU) with Pluristem, Fukushima University, Fukushima Global Medical Science Center, has been developing targeted animal models of ARS and has been testing these models in studies to evaluate the efficacy of PLX-R18 in treating radiation damage to the GI tract and bone marrow of mice.

  • GlobeNewswire2 months ago

    U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today it has entered into an additional collaboration agreement with the U.S. Department of Defense (DOD) and its United States Army Medical Research Institute of Chemical Defense (USAMRICD) to study the Company’s PLX-R18 cell therapy product in the treatment of long term lung injuries following exposure to mustard gas. The DOD is also studying the effectiveness of PLX-R18 as a novel medical countermeasure for Acute Radiation Syndrome (ARS) prior to exposure to high levels of radiation, designed to support the needs of the U.S. Armed Forces.

  • GlobeNewswire2 months ago

    Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results

    HAIFA, Israel, June 14, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by the Tel Aviv Stock Exchange ...

  • Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?
    Simply Wall St.2 months ago

    Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?

    In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pluristem Therapeutics Inc. (NASDAQ: PSTI ) stock ...

  • Reuters2 months ago

    Israel's Pluristem sees positive results from leg pain study

    Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent ...

  • GlobeNewswire2 months ago

    Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary Bio-Therapeutic approach.

  • Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock

    Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire3 months ago

    Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells in the treatment of Intermittent Claudication (IC) will be released on June 12, 2018. Pluristem's Phase II IC trial is evaluating the safety and efficacy of PLX-PAD cells as compared to placebo in 172 patients with IC, Rutherford category 2-3.

  • Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?
    Simply Wall St.3 months ago

    Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?

    Pluristem Therapeutics Inc’s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The US$156.33M market-cap posted a loss in its most recentRead More...

  • Associated Press3 months ago

    Pluristem: Fiscal 3Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 1 cent per share. The company's shares closed at $1.33. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights ...

  • Benzinga4 months ago

    FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next?

    Pluristem Therapeutics Inc. (NASDAQ: PSTI ), which develops placenta-based cell therapy products, announced Monday that the FDA cleared an investigational new drug application for PLX-R18 cell therapy ...

  • Benzinga4 months ago

    Benzinga Pro's 6 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Allergan plc (NYSE: AGN ) stock was trading higher ...

  • Reuters4 months ago

    FDA clears Pluristem radiation treatment for emergency use

    Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event. Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events. Full approval of the drug will depend on the results of a Phase III clinical trial.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MannKind Corporation (NASDAQ: MNKD ) stock was trading ...